<DOC>
	<DOCNO>NCT02452307</DOCNO>
	<brief_summary>The study evaluate prostate-specific antigen ( PSA ) response HLA-A*02 positive patient biochemical recurrence radical prostatectomy treat prostate-specific peptide vaccine combination different immune-adjuvants .</brief_summary>
	<brief_title>Peptide-specific Vaccination HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy</brief_title>
	<detailed_description>Patients biochemical recurrence initial therapy include .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>biochemical recurrence Radical Prostatectomy clinical metastasis CT bone scan HLAType : HLAA*02 positive KarnofskyPerformanceIndex &gt; 70 Age &gt; 45 / &lt; 80 year prior ongoing hormonal therapy ongoing radiation therapy SerumCreatinine &lt; 2mg/dl ; Bilirubin : &lt; 2gm/dl history allergy chronic obstructive lung disease ( COLD ) Patients unable consent KarnofskyPerformanceIndex &lt; 70 know allergy COLD presence secondary malignancy prior ongoing hormonal treatment ongoing radiotherapy immunosuppressive medication seizure</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>